{
    "nct_id": "NCT06607185",
    "official_title": "A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors",
    "inclusion_criteria": "* Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA\n* Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer\n* Have measurable disease per RECIST 1.1\n* Have an ECOG performance status of â‰¤1\n* Must not be pregnant and/or planning to breastfeed during the trial or within 180 days of the last dose of trial intervention\n* Must be able to swallow tablets\n* Participants with asymptomatic or treated CNS disease may be eligible\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have known active CNS metastases and/or carcinomatous meningitis\n* Have any unresolved toxicities from prior therapy greater than NCI CTCAE Version 5.0 Grade 1 at the time of starting trial treatment, except for alopecia, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy\n* Have significant cardiovascular disease defined as unstable angina or acute coronary syndrome, history of myocardial infarction, known left ventricular ejection fraction or heart failure, uncontrolled or symptomatic arrhythmias.\n* Have known active hepatitis B virus (HBV), hepatitis C virus (HCV) and untreated HIV infection\n* Have other active malignancy unless in remission with life expectancy greater than 2 years.\n* Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n* Have history of non-infectious pneumonitis/interstitial lung disease that received steroids or has current clinically significant pneumonitis/interstitial lung disease",
    "miscellaneous_criteria": ""
}